Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best healthcare stocks to buy for the long term. Canaccord cut the price target on ADMA Biologics Inc. (NASDAQ:ADMA) to $18 from $21 on May 7, reiterating a Buy rating on the shares. The firm told investors that fiscal Q1 2026 was a reset quarter for the company, with results falling short and guidance lowered primarily because of pressure on Bivigam within the standard IG market. It added that it is important to note that the key product and value driver, Asceniv, held up pretty well in fiscal Q1.

ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios

The rating update came after ADMA Biologics Inc. (NASDAQ:ADMA) reported its fiscal Q1 2026 earnings on May 6, with total revenue of $114.5 million, flat year-over-year. ASCENIV revenue for the quarter rose 28% year-over-year, while BIVIGAM revenue dropped 54% year-over-year. Management further reported that adjusted net income for fiscal Q1 2026 was $40.7 million, up 22% year-over-year, while adjusted EBITDA reached $59.7 million, reflecting a 24% year-over-year growth.

ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.

While we acknowledge the risk and potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADMA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.